This activity is for healthcare professionals outside of the UK.

This activity is provided by an independent medical education grant from Healthcare Business of Merck KGaA, Darmstadt, Germany. The activity is jointly provided by USF Health and touchIME.

Decline

Take CE/CME Test
Take CE/CME Test
Lung Cancer CE/CME ACCREDITED Watch Time: 55 mins

touchMDT Precision targeting of MET in NSCLC: A multidisciplinary approach

A multidisciplinary team of specialists discuss the use of targeted therapies for NSCLC with MET alterations.

 Overview & Learning Objectives
Patient with NSCLC with MET aberration
  • Targeting METex14 skipping mutations: Patient identification through molecular analysis
    Thoracic medical oncologist, interventional pulmonologist and molecular pathologist
    Play Arrow Watch Video

    Watch a thoracic medical oncologist, an interventional pulmonologist and a molecular pathologist discuss the case of an 81-year-old patient with NSCLC, and highlight best practices for molecular biomarker testing to identify METex14 skipping mutations.

    Time: 12:28
    Dr Le, Dr Argento, Prof. Stenzinger
    Play Arrow Watch Video
  • Managing METex14 skipping mutations: Clinical insights and strategies
    Thoracic medical oncologist, clinical oncology pharmacist and oncology nurse practitioner
    Play Arrow Watch Video

    Watch a thoracic medical oncologist, a clinical oncology pharmacist and an oncology nurse practitioner discuss the case of an 81-year-old patient with NSCLC with METex14 skipping mutation, and provide practical insights on treatment selection and patient management.

    Time: 14:45
    Dr Le, Dr Cuellar, Ms McDonald
    Play Arrow Watch Video
  • Metastatic challenges: Exploring MET amplification in refractory disease
    Thoracic medical oncologist, interventional pulmonologist and molecular pathologist
    Play Arrow Watch Video

    Watch a thoracic medical oncologist, an interventional pulmonologist and a molecular pathologist discuss the case of a patient with EGFR-TKI refractory NSCLC, including how to monitor and test for resistance to EGFR-TKIs and how to interpret molecular data to inform treatment decisions.

    Time: 14:50
    Dr Le, Dr Argento, Prof. Stenzinger
    Play Arrow Watch Video
  • Navigating resistance: MET-targeted treatment strategies for refractory NSCLC
    Thoracic medical oncologist, clinical oncology pharmacist and oncology nurse practitioner
    Play Arrow Watch Video

    Watch a thoracic medical oncologist, a clinical oncology pharmacist and an oncology nurse practitioner discuss treatment options and optimal management of a patient with EGFR-mutant NSCLC who develops resistance to EGFR-TKIs due to MET amplification.

    Time: 12:38
    Dr Le, Dr Cuellar, Ms McDonald
    Play Arrow Watch Video

Expert Spotlight

Dr Xiuning Le
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Dr Christine Argento
Johns Hopkins University School of Medicine, Baltimore, MD, USA
Prof. Albrecht Stenzinger
University Hospital Heidelberg, Germany

Dr Le, Dr Argento and Prof. Stenzinger discuss the case of an 81-year-old patient with NSCLC, and they highlight best practices for molecular biomarker testing to identify METex14 skipping mutations.

Get the Audio Version

Tutorial

This icon indicates there is a poll question. Click it when you see it to interact with your peers.

Poll

How confident do you feel in identifying oncogene driver mutations in patients with NSCLC?

Submit your answer to see the results

Not confident
   
A little confident
   
Moderately confident
   
Very confident
   
Thoracic medical oncologist, interventional pulmonologist and molecular pathologist
Get the Audio Version
Targeting METex14 skipping mutations: Patient identification through molecular analysis
Time: 12:28
Dr Le, Dr Argento, Prof. Stenzinger

Watch a thoracic medical oncologist, an interventional pulmonologist and a molecular pathologist discuss the case of an 81-year-old patient with NSCLC, and highlight best practices for molecular biomarker testing to identify METex14 skipping mutations.

Watch Next
Thoracic medical oncologist, clinical oncology pharmacist and oncology nurse practitioner

Managing METex14 skipping mutations: Clinical insights and strategies

Watch Now

Expert Spotlight

Dr Xiuning Le
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Dr Sandra Cuellar
University of Illinois at Chicago, Chicago, IL, USA
Ms Stephanie McDonald
Dana-Farber Cancer Institute, Boston, MA, USA

Dr Le, Dr Cuellar and Ms McDonald consider treatment options and optimal management of an 81-year-old patient with NSCLC bearing METex14 skipping mutations.

Get the Audio Version

Tutorial

This icon indicates there is a poll question. Click it when you see it to interact with your peers.

Poll

What is your main concern when treating a patient with NSCLC with METex14 skipping mutation?

Submit your answer to see the results

Treatment selection
   
Efficacy of MET TKIs
   
Side effects of MET TKIs
   
Impact of treatment on QoL
   
Thoracic medical oncologist, clinical oncology pharmacist and oncology nurse practitioner
Get the Audio Version
Managing METex14 skipping mutations: Clinical insights and strategies
Time: 14:45
Dr Le, Dr Cuellar, Ms McDonald

Watch a thoracic medical oncologist, a clinical oncology pharmacist and an oncology nurse practitioner discuss the case of an 81-year-old patient with NSCLC with METex14 skipping mutation, and provide practical insights on treatment selection and patient management.

Watch Next
Thoracic medical oncologist, interventional pulmonologist and molecular pathologist

Metastatic challenges: Exploring MET amplification in refractory disease

Watch Now

Expert Spotlight

Dr Xiuning Le
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Dr Christine Argento
Johns Hopkins University School of Medicine, Baltimore, MD, USA
Prof. Albrecht Stenzinger
University Hospital Heidelberg, Germany

Dr Le, Dr Argento and Prof. Stenzinger consider the case of a patient with EGFR-mutant NSCLC whose disease progresses under EGFR-TKI therapy. They discuss how to monitor and test for resistance to EGFR-TKIs and how to interpret molecular data to inform treatment decisions.

Get the Audio Version

Tutorial

This icon indicates there is a poll question. Click it when you see it to interact with your peers.

Poll

What is the main challenge you face when treating oncogene-addicted NSCLC which progresses after first-line targeted therapy?

Submit your answer to see the results

Identifying resistance mutations
   
Selecting second-line treatment
   
Communicating with the patient
   
Side effects of multiple treatments
   
Thoracic medical oncologist, interventional pulmonologist and molecular pathologist
Get the Audio Version
Metastatic challenges: Exploring MET amplification in refractory disease
Time: 14:50
Dr Le, Dr Argento, Prof. Stenzinger

Watch a thoracic medical oncologist, an interventional pulmonologist and a molecular pathologist discuss the case of a patient with EGFR-TKI refractory NSCLC, including how to monitor and test for resistance to EGFR-TKIs and how to interpret molecular data to inform treatment decisions.

Watch Next
Thoracic medical oncologist, clinical oncology pharmacist and oncology nurse practitioner

Navigating resistance: MET-targeted treatment strategies for refractory NSCLC

Watch Now

Expert Spotlight

Dr Xiuning Le
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Dr Sandra Cuellar
University of Illinois, Chicago, IL, USA
Ms Stephanie McDonald
Dana-Farber Cancer Institute, Boston, MA, USA

Dr Le, Dr Cuellar and Ms McDonald consider treatment options and optimal management of a patient with EGFR-mutant NSCLC who develops resistance to EGFR-TKIs due to MET amplification.

Get the Audio Version

Tutorial

This icon indicates there is a poll question. Click it when you see it to interact with your peers.

Poll

Which treatment do you usually consider for patients with NSCLC with MET amplification?

Submit your answer to see the results

Chemotherapy
   
MET-TKI
   
Immunotherapy
   
Other
   
Thoracic medical oncologist, clinical oncology pharmacist and oncology nurse practitioner
Get the Audio Version
Navigating resistance: MET-targeted treatment strategies for refractory NSCLC
Time: 12:38
Dr Le, Dr Cuellar, Ms McDonald

Watch a thoracic medical oncologist, a clinical oncology pharmacist and an oncology nurse practitioner discuss treatment options and optimal management of a patient with EGFR-mutant NSCLC who develops resistance to EGFR-TKIs due to MET amplification.

Watch Next
Thoracic medical oncologist, interventional pulmonologist and molecular pathologist

Targeting METex14 skipping mutations: Patient identification through molecular analysis

Watch Now
Back To Top
Overview & Learning Objectives
Overview

In this activity, five experts from the multidisciplinary team discuss the management of patients with advanced non-small cell lung cancer (NSCLC) bearing MET alterations. They consider biomarker testing, treatment selection and long-term care of patients newly diagnosed with METex14-mutated NSCLC, and patients who develop resistance to EGFR-targeted therapy due to MET amplification.

Target Audience

This activity has been designed to meet the educational needs of oncologists, respiratory specialists, pathologists, oncology nurse specialists and hospital pharmacists involved in the management of NSCLC.

USF Accreditation

Disclosures

USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.

Faculty

Dr Xiuning Le discloses: Advisory board or panel fees from Abbvie, Abion, Arrivent, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, EMD Serono (Merck KGaA), Hengrui Therapeutics, Janssen, Novartis, Regeneron, Sensei Biotherapeutics, Spectrum Pharmaceutics, SystImmune, Taiho, Teligene and Taiho. Consultancy fees from Abbvie, Abion, Arrivent, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Eli Lilly, EMD Serono (Merck KGaA), Hengrui Therapeutics, Janssen, Spectrum Pharmaceutics, Novartis, Regeneron, Sensei Biotherapeutics, Spectrum Pharmaceutics, SystImmune, Taiho and Teligene and Taiho. Grants/Research support from ArriVent, Boehringer Ingelheim, Dizal, Eli Lilly, EMD Serono, Janssen, Regeneron, Takeda, Teligene and Thermo Fisher Scientific.

Dr Christine Argento discloses: Advisory board or panel fees from Biodesix. Consultancy fees from Biodesix, Boston Scientific, Cook Medical, Intuitive Surgical and Olympus Therapeutics.

Dr Sandra Cuellar discloses: Advisory board or panel fees from Pharmacosmos (relationship terminated). Speaker’s bureau fees from Genentech and Seagen.

Ms Stephanie McDonald discloses: Consultancy fees from Pfizer.

Prof. Albrecht Stenzinger discloses: Advisory board or panel fees from AGCT, AstraZeneca, Bayer, BMS, Eli Lilly, Illumina, Janssen, MSD, Novartis, Pfizer, Roche, Seattle Genetics, Takeda and Thermo Fisher Scientific. Grants/research support from Bayer, BMS, Chugai and Incyte.

Content reviewer

Christy Thai, PharmD, BCPS and Alicia Canalejo, APRN have no financial interests/relationships or affiliations in relation to this activity.

Touch Medical Contributors

Adriano Boasso has no financial interests/relationships or affiliations in relation to this activity.

USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.

Requirements for Successful Completion

In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

If you have questions regarding credit please contact cpdsupport@usf.edu

Accreditations

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

USF Health designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Advanced Practice Providers

Physician Assistants may claim a maximum of 1 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.

Nurses

USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 1 contact hour may be earned by learners who successfully complete this continuing nursing education activity. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE activity.

This activity is awarded 1 ANCC pharmacotherapeutic contact hour.

Pharmacists

USF Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based program has been approved for 1 contact hour (0.1 CEUs).  Universal program number is as follows: UAN: 0230-9999-24-011-H01-P – 0.1 CEUs.

This activity can be viewed on any web browser such as, but not limited to, Google Chrome, Firefox, Safari, Opera, Microsoft Edge and Internet Explorer.

Date of original release:
PART 1: 16 October 2024
PART 2: 14 November 2024
Date credits expire: 14 November 2025

If you have any questions regarding credit please contact cpdsupport@usf.edu

Learning Objectives

After watching this activity, participants should be better able to:

  • Recognize the importance of identifying patients with MET alterations in NSCLC and choose the most appropriate strategy to detect specific gene alterations
  • Evaluate the evidence from completed or ongoing clinical trials on the use of MET inhibitors in selected patients with advanced NSCLC and implications for future practice
  • Apply clinical trial data on MET inhibitors in NSCLC, including adverse event management, using an holistic approach to patient care
Faculty & Disclosures
Dr Xiuning Le

University of Texas MD Anderson Cancer Center, Houston, TX, USA

Xiuning Le is an associate professor in the Department of Thoracic Head and Neck Medical Oncology at MD Anderson Cancer Center in Houston, TX, USA.read more

Dr Le received her MD from Peking Union Medical College in China and then obtained a PhD in genetics at Harvard Medical School in Massachusetts. Subsequently, she completed her internal medicine residency at the University of Massachusetts Medical Center and a Hematology/Oncology Fellowship at Beth Israel Deaconess Medical Center in Massachusetts. She joined MD Anderson Cancer Center as a faculty member in the Department of Thoracic Medical Oncology.

Dr Le’s clinical focus is on oncogene-driven lung cancers. She applies genomics expertise in her translational work to understand resistance mechanisms to targeted therapy and immunotherapy. She serves as a principal investigator for multiple trials focusing on EGFR-mutant or MET exon 14 skipping non-small cell lung cancer. Dr Le is a recipient of many prestigious awards, such as the Stand Up To Cancer (SU2C) V Scholar, American Society of Clinical Oncology (ASCO) Young Investigator and ASCO Career Development Awards.

Dr Xiuning Le discloses: Advisory board or panel fees from Abbvie, Abion, Arrivent, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, EMD Serono (Merck KGaA), Hengrui Therapeutics, Janssen, Novartis, Regeneron, Sensei Biotherapeutics, Spectrum Pharmaceutics, SystImmune, Taiho, Teligene and Taiho. Consultancy fees from Abbvie, Abion, Arrivent, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Eli Lilly, EMD Serono (Merck KGaA), Hengrui Therapeutics, Janssen, Spectrum Pharmaceutics, Novartis, Regeneron, Sensei Biotherapeutics, Spectrum Pharmaceutics, SystImmune, Taiho and Teligene and Taiho. Grants/Research support from ArriVent, Boehringer Ingelheim, Dizal, Eli Lilly, EMD Serono, Janssen, Regeneron, Takeda, Teligene and Thermo Fisher Scientific.
Dr Christine Argento

Johns Hopkins University School of Medicine, Baltimore, MD, USA

Christine Argento is an associate professor of medicine at The Johns Hopkins University in Baltimore, MD, USA, where she specializes in interventional pulmonology.read more

Dr Argento graduated from St. George’s University School of Medicine in Grenada, completed an internal medicine residency at the University of Medicine and Dentistry in New Jersey, a Pulmonary and Critical Care Fellowship at Yale University in Connecticut, and an additional fellowship in Interventional Pulmonology at Duke University, North Carolina.

Her main focus is on the diagnosis and palliation of patients with lung cancer and evaluation of pulmonary nodules and pleural disease. Her research involves new technologies that further the field of interventional pulmonology, increasing awareness of lung cancer and lung cancer screening, as well as disparities in lung cancer and procedural simulation education.

Dr Argento is vice president of the Association of Interventional Pulmonary Program Directors (AIPPD) and is a founding and board member of Women in Interventional Pulmonology (WiIP). She also holds leadership roles in national societies such as CHEST and the American Thoracic Society (ATS), as well as the American Association of Bronchial and Interventional Pulmonology (AABIP).

Dr Christine Argento discloses: Advisory board or panel fees from Biodesix. Consultancy fees from Biodesix, Boston Scientific, Cook Medical, Intuitive Surgical and Olympus Therapeutics.
Dr Sandra Cuellar

University of Illinois, Chicago, IL, USA

Sandra Cuellar is a clinical associate professor in the Department of Pharmacy at the University of Illinois at Chicago (UIC) College of Pharmacy and a clinical oncology pharmacist at the University of Illinois (UI) Health, both in Chicago, IL, USA. read more

She serves as the director of the oncology residency programme, member of the Data and Safety Monitoring Committee and co-chair of the Institutional Review Board at UI Health.

Dr Cuellar received her PharmD degree from the UIC College of Pharmacy, then completed a pharmacy practice residency at the University of Kentucky Chandler Medical Center in Kentucky, followed by a specialty oncology residency at MD Anderson Cancer Center in Texas.

Dr Cuellar is an editor-at-large for the Journal of Hematology Oncology Pharmacyand has served as an invited lecturer for national organizations including the Hematology/Oncology Pharmacy Association (HOPA), American Society of Health-System Pharmacists (ASHP), American College of Clinical Pharmacy (ACCP), Association of Community Cancer Centers (ACCC) and Academy of Managed Care Pharmacy (AMCP). Dr Cuellar was recently appointed a member of the ASHP Commission on Credentialing and she is the past chair of the Industry Relation Council for HOPA.

Dr Sandra Cuellar discloses: Advisory board or panel fees from Pharmacosmos (relationship terminated). Speaker’s bureau fees from Genentech and Seagen.
Ms Stephanie McDonald

Dana-Farber Cancer Institute, Boston, MA, USA

Stephanie McDonald is a nurse practitioner in the Thoracic Oncology Program at Dana-Farber Cancer Institute in Boston, MA, USA, with experience in medical oncology at Lahey Hospital and Medical Center in Massachusetts and the Genitourinary and Melanoma Program at Dartmouth-Hitchcock Medical Center in New Haven.read more

Ms McDonald’s clinical focus includes targeted therapies for lung cancer, managing immune checkpoint inhibitor toxicities, and improving chemotherapy education for patients and families.

Stephanie McDonald has presented at national and international conferences, and her work has been published in the Journal of Cancer Research and Clinical Oncology.

Ms Stephanie McDonald discloses: Consultancy fees from Pfizer.
Prof. Albrecht Stenzinger

University Hospital Heidelberg, Germany

Albrecht Stenzinger is professor of molecular tumour pathology and vice chair of the Institute of Pathology (IPH), as well as the director of the Center for Molecular Pathology at the IPH, University Hospital Heidelberg, Germany.read more

Prof. Stenzinger completed his MD degree at the University of Giessen, Germany, his residency and fellowship training in pathology at the Charité University Hospital in Berlin and the University Hospital Heidelberg, Germany, and is a board-certified surgical pathologist, a molecular pathologist and senior consultant pathologist. He received postdoctoral training at the University of Heidelberg and at Massachusetts General Hospital/Harvard Medical School, USA. He has broad expertise in molecular pathology and works primarily in translational research and genetics of solid tumours, including lung cancer.

Prof. Albrecht Stenzinger discloses: Advisory board or panel fees from AGCT, AstraZeneca, Bayer, BMS, Eli Lilly, Illumina, Janssen, MSD, Novartis, Pfizer, Roche, Seattle Genetics, Takeda and Thermo Fisher Scientific. Grants/research support from Bayer, BMS, Chugai and Incyte.
Downloads

View and download resources from this activity to support your learning and share with colleagues

Download Slides
Download Practice Aid
REGISTER NOW FOR FREE ACCESS TO:
  • 1000+ topical and insightful peer-reviewed journal articles
  • 100+ hours of bite-sized congress highlights
  • 10 major therapy areas packed with the latest scientific advances
  • 150+ specialties offering learn-on-the-go medical education
  • + Concise email updates and newsletters so you never miss out
Register For Free Now
This Activity Is Funded By:

An independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.

The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgement of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

USF

USF is an Equal Opportunity/Affirmative Action/Equal Access Institution.

USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

This content is intended for healthcare professionals outside the UK.

Date of original release:
PART 1: 16 October 2024
PART 2: 14 November 2024
Date credits expire: 14 November 2025

CE/CME Test (1 Points) Close
CE/CME Test

To obtain the CME credit(s), please complete this post-test. Please complete and click to see your results and continue.
Question 1/5
You are considering different methods of tissue collection for diagnosis, staging and biomarker testing for your patient with suspected NSCLC. Which considerations would you make when weighing the possibility of using EBUS-guided needle aspiration?

EBUS, endobronchial ultrasound; NSCLC, non-small cell lung cancer.
 Correct

EBUS-guided fine-needle aspiration is an accurate and minimally invasive method for establishing a histological diagnosis, for staging and for the genotyping of lung carcinomas.1 It has been shown to be as effective as surgical procedures for complete mutational testing of NSCLC by NGS.1,2

Abbreviations

EBUS, endobronchial ultrasound; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer.

References

  1. Ghigna MR, et al. J Thorac Dis. 2018;10:4653–8.
  2. Muriana P, Rossetti F. Mediastinum. 2020;4:23.
Question 2/5
Which of the following statements about DNA- and RNA-based NGS is true in relation to their applicability to the detection of METex14 skipping mutations?

NGS, next-generation sequencing.
 Correct

METex14 skipping can be caused by hundreds of distinct genetic alterations. RNA sequencing only needs to detect the direct result of alterations leading to METex14 skipping, the fusion of exons 13 and 15. Thus, DNA-based NGS has a higher rate of false negatives in detecting METex14 skipping than RNA-based NGS. Relative to DNA-based methods, METex14 detection with RNA NGS has been demonstrated to be superior.

Abbreviation

NGS, next-generation sequencing.

Reference

Socinski MA, et al. JCO Precis Oncol. 2021;5:PO.20.00516.

Question 3/5
You are assessing treatment options for your patient with NSCLC whose disease has progressed despite first-line osimertinib. Based on NCCN guidelines, in which situation would you consider adding a MET-TKI to the osimertinib regimen?

NCCN, National Comprehensive Cancer Network; NSCLC, non-small cell lung cancer; TKI, tyrosine kinase inhibitor.
 Correct

The NCCN guidelines list capmatinib, crizotinib or tepotinib as targeted therapy options for NSCLC with high-level MET amplification. High-level MET amplification, as detected by NGS-based methods, is defined as a copy number greater than 10. In patients with EGFR-mutant NSCLC who develop high-level MET amplifications, administration of capmatinib, crizotinib or tepotinib with continuation of osimertinib is acceptable.

Abbreviations

EGFR, epidermal growth factor receptor; NCCN, National Comprehensive Cancer Network; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer.

Reference

NCCN. Non-small cell lung cancer treatment guidelines. Version 10.2024 (accessed 14 October 2024).

Question 4/5
Which of the following is a common side effect of capmatinib and tepotinib?
 Correct

Oedema is the most common side effect with both capmatinib and tepotinib, reported by 59% and 81% of patients, respectively (all grades).1,2 Interstitial lung disease, pneumonitis and pruritus are clinically relevant adverse reactions occurring in <10% of patients treated with either of the two agents.1,2

References

  1. FDA. Capmatinib PI. 2024. Available at: www.accessdata.fda.gov/scripts/cder/daf/index.cfm (accessed 14 October 2024).
  2. FDA. Tepotinib PI. 2024. Available at: www.accessdata.fda.gov/scripts/cder/daf/index.cfm (accessed 14 October 2024).
Question 5/5
Your patient is a 71-year-old female with advanced NSCLC who is receiving tepotinib 450 mg daily. During a follow-up visit she complains of mild swelling of the limbs. You identify grade 2 peripheral oedema in the absence of significant laboratory abnormalities. What is your initial approach to managing the condition?

NSCLC, non-small cell lung cancer.
 Correct

Peripheral oedema is the most frequent side effect of tepotinib and can impair patient quality of life.1,2 In most cases, oedema is mild or moderate in nature, and can be easily managed.1,2 Conservative management can include compression garments, lymphatic massage and kinesiotherapy.2 Prescription of diuretics, such as furosemide, may be considered, but it is not recommended in clinical trials and PI.2 For side effects of grade 2 or lower, other than interstitial lung disease, tepotinib PI recommends to initially maintain the normal dose (450 mg daily); withholding tepotinib until side effect resolution and resuming treatment at a reduced dose is recommended only if the side effects become intolerable.1

References

  1. FDA. Tepotinib PI. 2024. Available at: www.accessdata.fda.gov/scripts/cder/daf/index.cfm(accessed 14 October 2024).
  2. Ahn L, et al. Clin J Oncol Nurs. 2022; 26:543–51.
Post Test Feedback Close
Step 1: Post CE/CME Test Feedback

Please note this feedback form is compulsory to complete your CE/CME evaluation

* = Mandatory Field

Please complete this short online feedback form.
Please indicate how well each statement met your expectations.
Accreditation Close
Accreditation

Please provide your details so that we can send you your certificate, which will be emailed to the address provided. All fields are required.

* = Mandatory Field
Your Accreditation Close
Your Accreditation

Thank you for your submission. Your certificate has been emailed to you.

Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup